Dibrugarh

Trauma is a major global health concern, and many training programs aim to improve how doctors initially manage trauma patients. Among these, the Advanced Trauma Life Support ATLS course is the most widely used, having trained over one million physicians worldwide. However, no controlled trials have yet shown whether ATLS improves patient outcomes, highlighting the need for research to compare ATLS training with standard care in adult trauma patients. The study compares the effects of ATLS training with standard care in hospitals in India that treat adult trauma patients. The ATLS intervention involves a 2.5-day course teaching a standardized approach to trauma care, including primary and secondary surveys, resuscitation, triage, and transfers. Physicians in the experimental group receive this accredited training, while the standard care group consists of usual trauma management by medical and surgical residents without specialized team approaches. Participants are adult trauma patients aged 15 years and older who present to participating emergency departments within 48 hours of injury and are admitted or transferred for admission. Researchers will collect routine hospital data and follow patients for 30 days after emergency department arrival to measure outcomes, focusing primarily on in-hospital mortality. The study uses an opt-out consent process for routine data and obtains informed consent for additional follow-up. Participation may last through hospital stay and 30-day post-arrival monitoring.

Researchers are evaluating whether Tranexamic Acid can improve outcomes in adults who have a spontaneous intracerebral haemorrhage, a type of stroke caused by bleeding within the brain. This trial focuses on patients who arrive within 4.5 hours after stroke symptoms begin. The study is important because this condition has a high risk of death and disability, and early treatment with haemostatic drugs like Tranexamic Acid could potentially reduce bleeding and improve recovery. The trial is conducted across multiple centers in India and aims to enroll 3400 patients. Participants will be randomly assigned to one of two groups. One group receives 2 grams of Tranexamic Acid given intravenously over 45 minutes, along with intensive blood pressure control to maintain systolic pressure below 140 mmHg for seven days. The other group receives standard care with the same blood pressure management protocol. Both groups will have CT brain scans after 24 hours to check for changes in bleeding. Blood pressure is closely monitored every 15 minutes for the first hour and then hourly for six hours. During the study, patients will be assessed using neurological scores on day 7 and their quality of life and functional status will be measured on day 90. Researchers will monitor death rates within 30 days, changes in haematoma size, neurological impairments, and overall recovery. The study includes regular neurological evaluations and brain imaging as needed. Participation lasts at least 90 days to evaluate outcomes and safety.